Pharma Spreads Its Bets On Multiple Modalities In Advanced Products
• By Pascal Joly, Ana Costa, and Markus Thunecke
Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.
Cell, gene and RNA therapies have been widely adopted by the major pharma players. While their growth is tremendous (52% CAGR up to 2026), they will only account for up to 7% of total market size by 2026.
The US Food and Drug Administration's (FDA) website currently references 23 approved cell and gene therapies, including six CAR-T products,...
